Corbion management presents strategic development update on ‘Advance 2025’
- 49
During its Capital Markets Update for analysts and investors in Amsterdam today, Corbion management will present a review of the ‘Advance 2025’ strategy development and introduce updated targets for the 2024-2025 period.
Key highlights
- Key financial metrics for 2023 in line with guidance1
- Emulsifier business divested (closing anticipated in Q2)
- EBITDA growth rate outlook for ‘24/’25 reconfirmed
- Restructuring program in place to deliver significant Free Cash Flow in ‘24/’25 (> € 125 million cum)
- Simplified business structure (two Business Units)
- Algae roadmap: Increased value creation potential at existing production facility (€ 200 million sales by 2028)
- Committed to PLA journey with focus on a differentiated strategy
- Biomedical polymers: Goal to double sales (> €100 million) in 5 years with limited investment
Olivier Rigaud, CEO of Corbion, comments:
“I am pleased to report a 2023 full year outcome in line with what we indicated in October of last year. This performance was realized in a challenging geopolitical and macro-economic environment. Although we see a sequential improvement in some of our key markets, we have embarked on a restructuring program, designed to achieve significant free cash flow delivery, and enabling leverage reduction. We have developed a simpler, more efficient and focused organization consisting of two business units and will implement appropriate measures to deliver annualized cost savings of around €55 million. The recent announcement of the disposal of our Emulsifier business not only completes a strategic realignment of our portfolio but also contributes to bolstering the balance sheet.”
Attachment
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
